Form 4: FibroBiologics CEO Granted Stock Options

FibroBiologics CEO Pete O'Heeron was granted options to purchase 453,000 shares of common stock on March 26, 2025.

Summary

• Pete O'Heeron, CEO of FibroBiologics, Inc., was granted stock options on March 26, 2025.
• The options allow him to purchase 453,000 shares of the company's common stock at an exercise price of $1.04 per share.
• The options vest over a period of four years, with one-fourth vesting after one year and the remaining balance vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The granting of stock options is a routine corporate action. It's neither overwhelmingly positive nor negative on its own.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology sector.
• The size and vesting schedule of the options granted to Pete O'Heeron would be compared to similar grants at companies of comparable size and stage of development, such as those in the Russell 2000 index or specific biotech indices.
• Companies like Amgen, Gilead Sciences, and Biogen offer comprehensive compensation packages to their executives, including stock options, restricted stock units, and performance-based bonuses.

Key Dates

Keywords

stock options, FibroBiologics, CEO, Pete O'Heeron, equity compensation, vesting, FBLG